- [PRESSWIRE] US – 19 September, 2020 – B Medical Systems, a leading European medical refrigeration and global vaccine cold chain manufacturer, is pleased to announce the official opening of its new 10,000 sq ft sales office and warehouse in Noblesville, Indiana. With over 40 years of experience in the medical refrigeration and vaccine cold chain market, the company offers a full line of medical-grade refrigerators, freezers, ultra-low temperature freezers, and transport devices designed for the safe storage and transport of biological materials, critical samples, blood, and vaccines.
- [PRESSWIRE] Vienna – 30th June 2020 — Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.
- [PRESSWIRE] LONDON, June 9, 2020 — Arix Bioscience plc (“Arix”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, Managing Director, will present at the Proactive One2One Virtual Biotech Forum on Thursday, 11 June 2020. Arix will be one of four companies presenting, each having a presentation slot followed by Q&A. The webinar will take place from 6.00pm and Arix will be the first company to present.
- [PRESSWIRE] Brussels – 2 June, 2020 — The EBRAINS shared Research Infrastructure for brain research is pleased to announce a significant step forward with the appointment of its founding CEO Paweł Świeboda. The EBRAINS digital brain research infrastructure is a key outcome of the European Commission’s Flagship 10-year research initiative Human Brain Project.
- [PRESSWIRE] Vienna – 4 June, 2020 — The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.
- [PRESSWIRE] Vienna – 2nd June 2020 — Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC).
- [PRESSWIRE] Frankfurt a. M., Germany & Haarlem, The Netherlands – 17 May, 2020 — FIZ (Frankfurt Biotechnology Innovation Center GmbH) and Sri Sri Tattva Europe B.V. collaborate to fight against COVID-19 through Ayurveda.
- [PRESSWIRE] Switzerland – 6 May, 2020 — Mootral was the front page of this Sunday’s New York Times Business Section in an explorative piece on the subject of cow emissions and solutions to curb them by Adam Satariano.
- [PRESSWIRE] Austria – 20 April, 2020 — Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.
- [PRESSWIRE] Charlotte, NORTH CAROLINA – 30 March, 2020 — Over the past two weeks, the leading magazine for autism families rapidly responded to the changing needs of the autism community by providing sought after autism COVID-19 resources. Autism Parenting Magazine Editor-in-Chief Amy KD Tobik said coming together to develop tools such as social stories and visual schedules, along with professional advice, was critical.
- [PRESSWIRE] Chicago, IL United States – 19 March, 2020 — Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care.
- [PRESSWIRE] Kuala Lumpur – December 31 2019 — Thomas Hafner, of Mootral, believes that his garlic supplement could cut methane emissions from cows by 38 per cent.
- [PRESSWIRE] France – 08 11 2019 -– In what represents a major milestone on the path to clinical application, a novel method to improve outcomes of Epilepsy surgery has now received approval for clinical testing in 13 French hospitals. The approach could provide a better therapeutic perspective against the drug-resistant form of the disease, which constitutes one third of all cases, and is a development by Human Brain Project scientist Viktor Jirsa and an interdisciplinary team of collaborators. To help clinicians plan surgery strategies, the scientists create personalized brain models of patients and simulate the spread of abnormal activity during epileptic seizures. The method represents the first example of a personalized brain modeling approach entering the clinic and will now be assessed over four years in a cohort of 356 patients under strict requirements.
- [PRESSWIRE] London – 09 July 2019 — The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients. Over 850 million people suffer from kidney diseases worldwide, a number which signifies epidemic proportions, yet these patients are still ignored by investigators and initiators of clinical trials in all medical fields – and are thus excluded from clinical trials. ASN, ERA-EDTA and ISN, collaboratively aim to bring about a paradigm change in medical research and have launched an information campaign to that end.
- [PRESSWIRE] Rolle, Switzerland – 16 May 2019 — Mootral is proud to announce that the Swiss Climate Foundation has endorsed and decided to help fund its efforts to protect the climate by reducing cattle’s methane emissions.
- [PRESSWIRE] SAN JOSE, Calif., March 21, 2019 — BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering. The gross proceeds of the offering are expected to be approximately $3.9 million.
- [PRESSWIRE] Weimar, Germany – 29 October, 2018 — The renewed interest in anti-GBM disease is spurred by the detection of autoantibodies in other forms of glomerulonephritis and has led to an exciting development in studies on pathogenesis as well as diagnosis and management. The newly published review [1] by Professor Mårten Segelmark, gives a comprehensive update on Anti-GBM disease subgroups, pathogenesis and therapies. “A must-read for all nephrologist”, explains Professor Denis Fouque, editor-in-chief of Nephrology Dialysis and Transplantation (NDT), the journal in which the review was published.
- [PRESSWIRE] SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 — Achieve Life Sciences, Inc. (NASDAQ :ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine.
- [PRESSWIRE] London, United Kingdom – 06 August, 2018 — The United Kingdom (UK) submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union (EU). This means that the United Kingdom will become a ‘third country’ from 30 March 2019. According to Directive 2001/83/EC the reference member state (RMS) must be a member of the EU.
- [PRESSWIRE] DURHAM, North Carolina, March 20, 2018 — Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio.
- [PRESSWIRE] LAS VEGAS, March 20, 2018 — The healthcare sector has always been one of the best performing industries in the stock market over the last several decades. In fact, since 1963 the healthcare sector has generated an annualized rate of return of 11 percent. Included in today’s commentary: Endonovo Therapeutics, Inc. (OTC: ENDV), Athersys, Inc. (NASDAQ: ATHX), Caladrius Biosciences (NASDAQ: CLBS), ARCA Biopharma, Inc. (NASDAQ: ABIO), Geron Corporation (NASDAQ: GERN).
- [PRESSWIRE] BERKELEY, California, March 6, 2018 — AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility is adding to its growing capacity with the addition of a 2000L single-use bioreactor (SUB).
- [PRESSWIRE] MONTREAL, February 16, 2018 — A consortium of companies comprising Air Liquide, AkzoNobel Specialty Chemicals, Enerkem and the Port of Rotterdam has signed a project development agreement covering initial investments in an advanced waste-to-chemistry facility in Rotterdam.
- [PRESSWIRE] PARIS and CAMBRIDGE, Massachusetts, January 4, 2018 — ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces that it has raised €32 million in a Series D financing.
- [PRESSWIRE] HSINCHU, Taiwan and WUHAN, China, Jan. 1, 2018 — JHL Biotech announced that Rong Chen has been appointed Chief Medical Officer effective January 1. As CMO, Dr. Chen will oversee JHL’s medical and clinical development work as part of its mission to make world-class biopharmaceuticals affordable and available to more patients.
- [PRESSWIRE] ROLLE, SWITZERLAND and the Arctic Circle, Finland – 19 December, 2017 — Santa’s famous and much beloved reindeer are part of the ruminant animal family and therefore produce harmful greenhouse gases. It is said that Santa’s nine reindeer in total travel more than 342 million kilometres around the world on their mission to deliver Christmas presents to eager children, and as a result produce roughly 15 tons of methane gas a year.
- [PRESSWIRE] WATERTOWN, Mass. – 29 February, 2016 –Tarveda Therapeutics, Inc., today announced that Drew Fromkin, President and Chief Executive Officer of Tarveda Therapeutics, is scheduled to present at the upcoming Cowen and Company 36th Annual Health Care Conference in Boston, on Monday, March 7, at 2:00 p.m. ET.
- [PRESSWIRE] WASHINGTON – 30 March, 2016 — The Biotechnology Innovation Organization (BIO) announced today that President and CEO of NexSteppe, Anna Rath, has been selected by a committee of her peers to be the recipient of the 2016 BIO Rosalind Franklin Award. The Rosalind Franklin Award was established by BIO to honor an outstanding woman in the field of industrial biotechnology.
- [PRESSWIRE] Tomsk, Russia – 05.04.16 – New research identifies the historical trends that suggest we should be worried about the planet’s future…
- [PRESSWIRE] CAMBRIDGE, England – 11 April, 2016 — Genestack, the developer of a next generation enterprise platform for genomics research and development, has partnered with the Cancer Molecular Diagnostic Laboratory (CMDL), an organisation involving Cancer Research UK, the University of Cambridge, the Cambridge University Hospitals NHS Trust and the Medical Research Council, to bring advanced genomic technologies into clinical practice.